NEW YORK — Clinical genomics informatics firm PierianDx said on Monday that it has closed a $27 million Series B financing round.
The round was led by ATW Partners and SJF Ventures, and included existing investors Health Catalyst Capital, Inova Health Systems, RTI International, and ARUP Laboratories.
St. Louis, Missouri-based PierianDx offers products and services for analyzing, interpreting, and reporting clinical next-generation sequencing data with a focus on cancer.